Tweet
Regrow ACT : to Speed Development of Regenerative Medicine
Senator Kirk (U.S) said
"From the Kirk press release:
“Unfortunately the Food and Drug Administration (FDA) has identified the current lack of regulatory standards in this area of medicine as an impediment to treatment development. Countries like Japan and England are outpacing the U.S. in regenerative medicine therapy development due to new regulatory policies that the U.S. has yet to mirror.
S. 2689 will allow the United States to regain prominence in the field of regenerative medicine science and bring therapies quickly to the patients that need it most.”
Mike Coffman:
“The development of regenerative medical treatments is one of the most exciting aspects of modern medicine. These products, developed from adult stem cells, show potential to fully restore or establish normal function in damaged human cells, tissues, or organs,” said Coffman.
Currently, the Food and Drug Administration (FDA) oversees the development of regenerative applications based on a patchwork of regulations. The FDA simply does not have an approval process in place to best consider these new, innovative therapies. As a result, other countries, particularly Japan and the United Kingdom, are quickly outpacing the United States in the development of regenerative treatments".
Sources :
"From the Kirk press release:
“Unfortunately the Food and Drug Administration (FDA) has identified the current lack of regulatory standards in this area of medicine as an impediment to treatment development. Countries like Japan and England are outpacing the U.S. in regenerative medicine therapy development due to new regulatory policies that the U.S. has yet to mirror.
S. 2689 will allow the United States to regain prominence in the field of regenerative medicine science and bring therapies quickly to the patients that need it most.”
Mike Coffman:
“The development of regenerative medical treatments is one of the most exciting aspects of modern medicine. These products, developed from adult stem cells, show potential to fully restore or establish normal function in damaged human cells, tissues, or organs,” said Coffman.
Currently, the Food and Drug Administration (FDA) oversees the development of regenerative applications based on a patchwork of regulations. The FDA simply does not have an approval process in place to best consider these new, innovative therapies. As a result, other countries, particularly Japan and the United Kingdom, are quickly outpacing the United States in the development of regenerative treatments".
Sources :
Comment